LMR Partners’s Health Catalyst HCAT Stock Holding History

LMR Partners’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-51,011	Closed	-$2.55M	–	1199
2021 Q3	$2.55M	Buy	+51,011	New	+$2.78M	0.03%	397

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

LMR Partners's HCAT Position: Q4 2021 in Review

LMR Partners sold out of Health Catalyst (HCAT) in Q4 2021, closing a stake of 51,011 shares — an estimated $2.55M sold.

LMR Partners first reported a position in HCAT in Q3 2021 and held it in 1 quarter. The position peaked at $2.55M in Q3 2021. 186 funds tracked by Wall St. Rank hold HCAT as of Q4 2021.

LMR Partners reported no remaining Health Catalyst position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 51,011 Health Catalyst shares in Q4 2021, an estimated $2.55M.
LMR Partners first reported a position in Health Catalyst in Q3 2021 and held it in 1 quarter.
LMR Partners's Health Catalyst position peaked at $2.55M in Q3 2021.
186 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.